A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Conditions
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder · Major Depressive Disorder · Tardive Dyskinesia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Neurocrine Clinical Site, Bryant, Arkansas, United States
Neurocrine Clinical Site, Chino, California, United States
Neurocrine Clinical Site, Fountain Valley, California, United States
Neurocrine Clinical Site, Fresno, California, United States
Neurocrine Clinical Site, Long Beach, California, United States
Neurocrine Clinical Site, Orange, California, United States
Neurocrine Clinical Site, Redlands, California, United States
Neurocrine Clinical Site, San Diego, California, United States
Neurocrine Clinical Site, Bonita Springs, Florida, United States
Neurocrine Clinical Site, Hialeah, Florida, United States
Neurocrine Clinical Site, Miami, Florida, United States
Neurocrine Clinical Site, Miami, Florida, United States
Neurocrine Clinical Site, Orange City, Florida, United States
Neurocrine Clinical Site, Port Charlotte, Florida, United States
Neurocrine Clinical Site, Tampa, Florida, United States
Neurocrine Clinical Site, Augusta, Georgia, United States
Neurocrine Clinical Site, Marietta, Georgia, United States
Neurocrine Clinical Site, Naperville, Illinois, United States
Neurocrine Clinical Site, Omaha, Nebraska, United States
Neurocrine Clinical Site, Independence, Ohio, United States
Neurocrine Clinical Site, Austin, Texas, United States
Neurocrine Clinical Site, Richmond, Virginia, United States
Study leads
Clinical Development Lead
Study Director
Neurocrine Biosciences